Trends & Analysis

#2025 predictions #Drug development #Drug discovery #Regulatory

Regulation and drug policy: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience, cancer research, cell and gene therapy and diagnostics. Here, looking at regulation and drug policy.  Ariel… Read More

#Exclusive Content #Regulatory #Trends & Analysis

Rare diseases
#Data #Rare disease #Rare Disease Day

Rare disease research is changing, data says

This Rare Disease Day, Elsevier’s Scopus research and citation database analyses articles from millions of researchers, institutions and companies around the world to present data that suggests rare disease research has skyrocketed over the last ten years, but is starting to level off. According to the data, there was a… Read More

#News #Trends & Analysis

#GLP-1 #Market reporting #Novo Nordisk #Obesity #Scandinavia #Weight loss

What effect have weight loss drugs had on the Scandinavian economy?

In less than a decade GLP-1 receptor agonists have transformed the treatment of obesity and made Novo Nordisk Europe’s most valuable company. Diana Spencer explores the current impact and potential future for these drugs. Originally designed in Scandinavia as a maintenance therapy for type 2 diabetes, GLP-1 receptor agonists are… Read More

#Exclusive Content #Market Reports #Trends & Analysis

#2025 predictions #Diagnostics #Drug discovery

Diagnostics: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience, cancer research and cell and gene therapy. Here, looking through a diagnostics lens.  Jackie… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

#2025 predictions #Cell and gene therapy #Drug discovery

Cell and gene therapy: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience and cancer research. Here, looking at cell and gene therapy. For the last few… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

#2025 predictions #Cancer #Cancer research #Drug discovery

Cancer burden and research: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience. Here, looking at cancer burden and research in the sector. Ahead of World Cancer Day… Read More

#Business & Investment #Cancer Research #Exclusive Content #Trends & Analysis

#2025 predictions #Drug discovery #Neuroscience

Neuroscience: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, this was with a focus on technology, machine learning (ML) and artificial intelligence (AI). Here, looking at the neuroscience sector. At the Society for Neuroscience’s annual meeting, Neuroscience 2024, both the… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

#Artificial intelligence (AI) #Automation / robotics #Lab automation #Market reporting #Survey

AI is the automation trend researchers are most excited about

When it comes to future developments in lab automation technology, the integration of artificial intelligence (AI) is the top area of anticipation for drug discovery labs.   This is one of the key findings of the DDW Research & Consultancy 2025 Research Report Purchasing in Drug Discovery… Read More

#Editor's Choice #News #Trends & Analysis

#2025 predictions #Artificial intelligence (AI) #Drug discovery #Lab technology #Machine learning

Tech, ML and AI: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Here, the focus is on technology, machine learning (ML) and artificial intelligence (AI). In a prediction piece written for Forbes, contributor Bernard Marr outlined five key technology trends for 2025 across multiple industries1. With… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

#Biopharmaceuticals #Clarivate #Market reporting #Small molecules

Eleven drugs tipped for blockbuster status by 2030

Eleven drugs are projected to achieve blockbuster status or revolutionise treatment paradigms within five years, according to Clarivate’s 2025 Drugs to Watch report.  The drugs address critical challenges in areas such as obesity, oncology, and gene therapy, and are forecast to achieve blockbuster sales by 2030 or… Read More

#Editor's Choice #News #Trends & Analysis

Neuroscience Parkinson's disease
#Bayer #Biogen #BlueRock Therapeutics #Cell therapy #Ionis Pharmaceuticals #Mission Therapeutics #Neuroscience #Parkinson's #Small molecul #Stem cells #Vaxxinity #Vesper Bio

Exploring new frontiers in Parkinson’s Disease   

With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW’s Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition.  Parkinson’s is the most common movement disorder, affecting… Read More

#Exclusive Content #Trends & Analysis

SLAS Europe 2024
#AI / data analytics / healthtech / informatics #Awards #Drug discovery #Lab automation #Life sciences #Machine learning #SLAS2024

SLAS Europe 2024 in summary  

DDW Multimedia Editor Megan Thomas travelled to SLAS Europe from 27-29 May in Barcelona, Spain. Having attended a range of sessions and spoken to industry attendees and exhibitors, she reflects on the event.   Opening keynote  Professor Luis Serrano presented the opening keynote of the event on engineering… Read More

#Exclusive Content #Trends & Analysis

#AAV #Astrea Bioseparations #Cell and gene therapy #Exosomes #Molecular Biology

The democratisation of cell and gene therapy

Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. Lack of standardisation According to Hummersone, the major challenge in the CGT space is a lack of throughput that’s due to… Read More

#Exclusive Content #Opinion #Trends & Analysis